Federated Hermes Inc. Sells 1,425 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Federated Hermes Inc. reduced its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 14.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,651 shares of the life sciences company’s stock after selling 1,425 shares during the quarter. Federated Hermes Inc.’s holdings in Integra LifeSciences were worth $377,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IART. Gladius Capital Management LP bought a new stake in Integra LifeSciences in the third quarter worth about $47,000. Covestor Ltd raised its stake in shares of Integra LifeSciences by 82.5% during the third quarter. Covestor Ltd now owns 2,037 shares of the life sciences company’s stock valued at $78,000 after acquiring an additional 921 shares in the last quarter. International Assets Investment Management LLC bought a new position in shares of Integra LifeSciences during the 4th quarter worth $190,000. Empirical Asset Management LLC bought a new position in Integra LifeSciences during the 4th quarter worth about $212,000. Finally, Panagora Asset Management Inc. purchased a new position in Integra LifeSciences during the third quarter valued at approximately $223,000. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on IART. StockNews.com downgraded shares of Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Tuesday, April 30th. JMP Securities reduced their target price on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a research report on Thursday, February 29th. Citigroup raised Integra LifeSciences from a “sell” rating to a “neutral” rating and set a $38.00 price target for the company in a report on Wednesday, April 3rd. Finally, Truist Financial cut their price objective on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a report on Friday, March 1st. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $44.89.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $28.89 on Friday. The company has a 50 day moving average price of $33.75 and a 200-day moving average price of $38.44. Integra LifeSciences Holdings Co. has a 1-year low of $27.18 and a 1-year high of $51.12. The firm has a market cap of $2.27 billion, a price-to-earnings ratio of 34.81, a price-to-earnings-growth ratio of 0.87 and a beta of 1.17. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.01). The firm had revenue of $397.00 million for the quarter, compared to analysts’ expectations of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. The company’s revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.94 earnings per share. Equities research analysts forecast that Integra LifeSciences Holdings Co. will post 3.19 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.